WALTHAM, Mass., March 25, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the completion of its previously announced merger with Homology Medicines, Inc. ("Homology"). The combined company will operate under the name Q32 Bio, and its shares are expected to begin trading on the Nasdaq Global Market on March 26, 2024, under the ticker symbol "QTTB".
WALTHAM, Mass., Feb. 21, 2024 /PRNewswire/ -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the publication of preclinical data in Molecular Therapy that further validates the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor. The paper, titled "C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement," was co-authored by Q32 Bio scientists Fei Liu, Ph.D., and Sarah Ryan, with Chief Scientific Officer Shelia Violette, Ph.D., and Stefan Wawersik, Ph.D., Vice President and Head of Research at Q32 Bio as senior authors.
SAN FRANCISCO, Calif. and BOULDER, Colo.—January 16, 2024 – Innovaccer Inc., today announced that it has acquired a 100% stake in Cured, a leading digital marketing and CRM platform for healthcare. This strategic move marks a significant milestone in Innovaccer’s commitment to revolutionize healthcare. With this transaction, Innovaccer will add over 20 health systems and digital health clients to the company’s current portfolio of over 95 customers.
NEW HAVEN, CONNECTICUT, USA, January 9, 2024 /EINPresswire.com/ -- Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series A funding round.
The funding will support the rapid expansion of life-saving services targeting youth and adults nationwide. The Vita behavioral health care pathways are based on the founding team’s successful clinical trials published in JAMA, The American Journal of Psychiatry and thousands of patient encounters demonstrating reductions in suicide attempts by more than 60% and deaths by up to 80%.
In this episode of the CU Anschutz 360 podcast, Daniel LaBarbera, PhD, director of the Center for Drug Discovery, talks about harnessing technology and innovation to speed the development of new therapies. He discusses robotic automation, quantum computing and building bridges over the ‘valley of death.’